Lassen et al reported that p16INK4a-positive HNSCC showed a better response to conventional radiotherapy than p16INK4a-negative HNSCC, and ascribed this survival benefit to a better locoregional control rate (13). This evidence concerns the gene CDKN2A and head and neck squamous cell carcinoma.